

121. (Amended) The recombinant host cell of Claim 97, wherein the recombinant host cell is a eukaryotic cell.

122. (Amended) The recombinant host cell of Claim 121, wherein the eukaryotic cell is a mammalian cell.

124. (Amended) The recombinant host cell of Claim 106, wherein the recombinant host cell is a Chinese Hamster Ovary cell.

125. (Amended) The recombinant host cell of Claim 108, wherein the recombinant host cell is a Chinese Hamster Ovary cell.

126. (Amended) The recombinant host cell of Claim 110, wherein the recombinant host cell is a Chinese Hamster Ovary cell.

127. (Amended) The recombinant host cell of Claim 112, wherein the recombinant host cell is a Chinese Hamster Ovary cell.

128. (Amended) The recombinant host cell of Claim 121, wherein the eukaryotic cell is a yeast cell.

131. (Amended) A process of producing a recombinant polypeptide having the ability to bind TNF comprising culturing the recombinant host cell of Claim 97 under suitable conditions to express the polypeptide.

132. (Amended) The process of claim 131, further comprising culturing the recombinant host cell under suitable conditions to amplify the recombinant nucleic acid molecule.

148. (Amended) The process of Claim 146, wherein said recovered polypeptide is formulated to comprise said polypeptide and a pharmaceutically acceptable carrier.

Please add the following new claims.

149. The recombinant host cell of Claim 104, wherein the recombinant host cell is a prokaryotic cell.

150. The recombinant host cell of Claim 149, wherein the prokaryotic cell is *Escherichia coli*.

151. The recombinant host cell of Claim 104, wherein the recombinant host cell is a eukaryotic cell.

152. The recombinant host cell of Claim 151, wherein the eukaryotic cell is a mammalian cell.

153. The recombinant host cell of Claim 152 wherein the mammalian cell is a Chinese Hamster Ovary cell or a COS cell.

154. The recombinant host cell of Claim 151, wherein the eukaryotic cell is a yeast cell.

155. A process of producing a recombinant polypeptide having the ability to bind TNF comprising culturing the recombinant host cell of Claim 104 under suitable conditions to express the polypeptide.

156. The process of Claim 155, wherein the recombinant host cell is a prokaryotic cell.

157. The process of Claim 156, wherein the prokaryotic cell is *Escherichia coli*.

158. The process of Claim 155, wherein the recombinant host cell is a eukaryotic cell.
159. The process of Claim 158, wherein the eukaryotic cell is a mammalian cell.
160. The process of Claim 159, wherein the mammalian cell is a Chinese Hamster Ovary cell or a COS cell.
161. The process of Claim 158, wherein the eukaryotic cell is a yeast cell.
162. The process of Claim 155, wherein said polypeptide is expressed as a multimer.
163. The process of Claim 155, further comprising recovering the polypeptide from the culture.
164. The process of Claim 163, further comprising chemically derivatizing the recovered polypeptide.
165. The process of Claim 164, wherein said recovered polypeptide is formulated to comprise said polypeptide and a pharmaceutically acceptable carrier.
166. The process of Claim 163, wherein said recovered polypeptide is formulated to comprise said polypeptide and a pharmaceutically acceptable carrier.
167. A process comprising culturing the recombinant host cell of Claim 104 under suitable conditions to amplify the nucleic acid molecule.
168. A process of producing a recombinant polypeptide having the ability to bind TNF comprising culturing a recombinant host cell comprising a nucleic acid molecule that encodes a polypeptide consisting of the amino acid sequence of SEQ ID NO: 4 and an amino-terminal

methionine under suitable conditions to express the polypeptide.

169. A process of producing a recombinant polypeptide having the ability to bind TNF comprising culturing a recombinant host cell comprising a nucleic acid molecule that encodes a polypeptide consisting of a C-terminally shortened sequence of the amino acid sequence of SEQ ID NO: 4 and an amino-terminal methionine under suitable conditions to express the polypeptide.

170. A process of producing a recombinant polypeptide having the ability to bind TNF comprising culturing a recombinant host cell comprising a nucleic acid molecule that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO: 4 under suitable conditions to express the polypeptide.

171. A process of producing a recombinant polypeptide having the ability to bind TNF comprising culturing a recombinant host cell comprising a nucleic acid molecule that encodes a polypeptide comprising a C-terminally shortened sequence of the amino acid sequence of SEQ ID NO: 4 under suitable conditions to express the polypeptide.

172. A process of producing a recombinant polypeptide having the ability to bind TNF comprising culturing a recombinant host cell comprising a nucleic acid molecule that encodes a polypeptide consisting of the amino acid sequence of SEQ ID NO: 4 under suitable conditions to express the polypeptide.

173. A process of producing a recombinant polypeptide having the ability to bind TNF comprising culturing a recombinant host cell comprising a nucleic acid molecule that encodes a polypeptide consisting of a C-terminally shortened sequence of the amino acid sequence of SEQ ID NO: 4 under suitable conditions to express the polypeptide.

174. The process of any of Claims 168, 169, 170, 171, 172, or 173, wherein the recombinant host cell is a prokaryotic cell.

175. The process of Claim 174, wherein the prokaryotic cell is *Escherichia coli*.

176. The process of any of Claims 168, 169, 170, 171, 172, or 173, wherein the recombinant host cell is a eukaryotic cell.

177. The process of Claim 176, wherein the eukaryotic cell is a Chinese Hamster Ovary cell.

178. The process of Claim 147, wherein said recovered polypeptide is formulated to comprise said polypeptide and a pharmaceutically acceptable carrier.

### **REMARKS**

Claims 75, 114, 121, 122, 124-128, 131, 132, and 148, as amended; claims 27-74, 76-113, 115-120, 123, 129, 130, 133-135, 138, 139, and 144-147 as filed; and new claims 149-178 are pending in the instant application. Claims 19-21, 24-26, 136, 137, and 140-143 have been canceled without prejudice or disclaimer. Support for the amendments to the claims can be found in the specification at, for example, page 65, lines 17-28. No new matter has been added as a result of the above-described amendments. The rejections set forth in the Office Action have been overcome by amendment or are traversed by argument below.

#### **1. Information Disclosure Statement**

The Office Action states that certain references listed on the Information Disclosure Statement filed October 24, 2000 were not present, and therefore, have not been considered. Applicants hereby file a Supplemental Information Disclosure Statement listing six of the eight references from the Information Disclosure Statement filed October 24, 2000 that have not yet been considered. Because Applicants have been unable to locate copies of the remaining references in their own file (*i.e.*, Powell *et al.*, 1990, *Int. Immunol.* 2:539-44; Tsujimoto *et al.*, 1987, *Tumor Necrosis Factor and Related Cytotoxins*, pp. 88-108), new copies of these references have been ordered, and Applicants will promptly submit these references with a Second Supplemental